Compare Inovio Pharmaceuticals Inc (INO) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Lamb Weston Holdings Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while Lamb Weston Holdings Inc trades at $46.42 (market cap $6.43B). The key difference: Lamb Weston Holdings Inc is far larger — about 72× Inovio Pharmaceuticals Inc's market cap, and Lamb Weston Holdings Inc pays a 3.26% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | LW | |
|---|---|---|
Market Cap | $89.27M | $6.43B |
Sector | Health | Consumer Staples |
52-Week High | $2.87 | $66.57 |
52-Week Low | $1.05 | $38.48 |
Enterprise Value | $60.28M | $10.40B |
Dividend Yield | — | 3.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
Lamb Weston (LW) trades at $47.26, up 1.0% on the day, with a bullish technical signal from moving averages. The stock shows consistent earnings beats in recent quarters, with Q2 2026 results pending. Revenue reached $6.45B in 2025, though net income margin compressed to 4.61%. Analyst consensus is a $49.33 price target with a mixed buy/hold rating split. Recent news highlights the company's 'Focus to Win' strategy driving North America volume gains and cost savings, alongside ongoing legal challenges.
LW presents a turnaround story with cost-saving initiatives and market share gains supporting upside potential. However, margin pressures, a pending securities lawsuit, and high debt levels pose significant risks. The stock's valuation at a P/E of 21.88 appears reasonable if earnings growth resumes, but investors face headwinds from competitive and operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
